Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitors, which are now standard in the maintenance setting following first-line chemotherapy. This retrospective cohort study investigates the real-world effectiveness and safety of olaparib, a PARP inhibitor, in patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD positive but BRCA wild-type, a demographic less extensively explored in previous research. The primary goal was to assess the 1-year progression-free survival (PFS) rate of olaparib maintenance therapy in this specific patient group, offering insights into its potential as a therapeutic option.
Conducted across 11 high-volume tertiary care centers in China, the study included patients who received olaparib as frontline maintenance therapy after achieving a complete or partial response to platinum-based chemotherapy. The analysis focused on the 1-year PFS rate, median PFS, time to first subsequent therapy or death, and treatment-related adverse events. The 1-year PFS rate was 75.
2%, with a median PFS of 21.0 months, aligning with previous trials and highlighting olaparib's efficacy in maintaining remission in patients with HRD-positive, BRCA wild-type ovarian cancer. The safety profile of olaparib was consistent with known adverse events, primarily anemia and nausea, with most patients continuing treatment without.